The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor purity as confounder for the determination of tumor mutational burden (TMB).
 
Susanne Beck
No Relationships to Disclose
 
Michael Menzel
Stock and Other Ownership Interests - Illumina
 
Daniel Kazdal
Honoraria - Agilent; AstraZeneca; Bristol-Myers Squibb; Illumina; Lilly; Pfizer; Takeda
 
Peter Schirmacher
Honoraria - BMS; Eisai Germany; Incyte; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai Germany; Incyte; MSD; Novartis; Roche
Speakers' Bureau - BMS GmbH & Co. KG; Incyte
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
 
Albrecht Stenzinger
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; Incyte; Janssen; Lilly; MSD; Novartis; SERVIER; Takeda; Thermo Fisher Scientific
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; MSD; Novartis; Roche; SERVIER; Thermo Fisher Scientific
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Incyte
 
Jan Budczies
Consulting or Advisory Role - Merck Sharp & Dohme